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Background. The English Department of Health has intro-
duced routine collection of patient-reported outcome data
for selected surgical procedures to facilitate patient choice
and increase hospital accountability. However, using
aggregate health outcome scores, such as EQ-5D utilities,
for performance assessment purposes causes information
loss and raises statistical and normative concerns. Objec-
tives. For hip replacement surgery, we explore a) the
change in patient-reported outcomes between baseline
and follow-up on 5 health dimensions (EQ-5D), b) the
extent to which treatment impact varies across hospitals,
and c) the extent to which hospital performance on EQ-
5D dimensions is correlated with performance on the
EQ-5D utility index. Methods. We combine information
on pre- and postoperative EQ-5D outcomes with routine
inpatient data for the financial year 2009–2010. The sam-
ple consists of 21,000 patients in 153 hospitals. We
employ hierarchical ordered probit risk-adjustment mod-
els that recognize the multilevel nature of the data and
the response distributions. The treatment impact is
modeled as a random coefficient that varies at the hospital
level. We obtain hospital-specific empirical Bayes (EB) es-
timates of this coefficient. We estimate separate models
for each EQ-5D dimension and the EQ-5D utility index
and analyze correlations of EB estimates across these. Re-
sults. Hospital treatment is associated with improvements
in all EQ-5D dimensions. Variability in treatment impact
is most pronounced on the mobility and usual activities
dimensions. Conversely, only pain/discomfort and anxi-
ety/depression correlate well with performance measures
based on utilities. This leads to different assessments of
hospital performance across metrics. Conclusions. Our re-
sults indicate which hospitals are better than others in
improving health across particular EQ-5D dimensions.
We demonstrate the importance of evaluating dimensions
of the EQ-5D separately for the purposes of hospital per-
formance assessment. Key words: EQ-5D; patient-
reported outcomes (PRO); hierarchical ordered probit;
provider profiling; quality measurement; performance
assessment. (Med Decis Making 2013;33:804–818)
Recent years have seen a growing trend to mea-sure and publish hospital data on health out-
comes to facilitate patient choice and increase
provider accountability.1,2 The focus of these
activities has been on measures of mortality, read-
mission, or adverse events, which are easily derived
from clinical records but reveal little about the
health of the vast majority of patients. To allow for
a more sensitive assessment of hospital perfor-
mance, it is necessary to move away from a focus
on relatively rare ‘‘failure’’ outcomes toward more
comprehensive and sensitive measures of patients’
health outcomes.3–5
Since April 2009, all providers of publicly funded
inpatient care in the English National Health Service
(NHS) have been required to collect both EQ-5D6 and
condition-specific data for 4 elective procedures: uni-
lateral hip and knee replacements, varicose vein sur-
gery, and groin hernia repairs.7 Eligible patients are
invited to report their health status before and 3 or 6
months after surgery. The changes in patients’ health
status are expected to ‘‘provide an indication of the
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outcomes or quality of care delivered to NHS
patients’’7(p5) and can be analyzed to identify system-
atic variation across hospital providers with finer
granularity than previously possible.
Traditionally, patient-reported outcome (PRO)
measures have been collected and analyzed primarily
within clinical trials to assess the treatment effect on
patients’ health. Their application in the context of
routine performance assessment on a national scale
breaks new ground and requires an appropriatemeth-
odology that takes into account the characteristics of
the data and their intended use asmeasures of the rel-
ative quality of hospital treatment.8
The NHS Information Centre has developed a pre-
liminary risk-adjustment methodology that is cur-
rently being applied to the PRO data.9 For the EQ-
5D, this involves transforming the patients’ EQ-5D
health profiles into utility-weighted index scores
and estimating multivariate regression models to
relate posttreatment utility scores to the pretreatment
scores and case-mix controls. The advantage of this
approach is that patient health is expressed in terms
of a (quasi-)continuous score, which facilitates statis-
tical analysis and allows for ranking of hospitals with
respect to a single performancemetric: their ability to
influence posttreatment utilities or, equivalently,
changes in scores over time. However, for the purpo-
ses of performance measurement, identifying best
practice, and informing patient choice, the costs of
aggregation may outweigh the benefits. We build
this argument around 3 points.
First, any form of aggregation causes loss of detail
and information.10 Once constructed, an index mea-
sure cannot reveal information about the underlying
components and the degree to which hospitals affect
these. Certain hospitals may performwell on one EQ-
5D dimension but fall short on another. Detailed
information on the performance on each dimension
can help to identify the source of the problem and fos-
ter improvement through adoption of best practice.10
Second, the use of an aggregation function introdu-
ces exogenous variation that can bias statistical infer-
ence and raises normative concerns about whose
preferences the weights should reflect.10,11 In some
circumstances, one may be willing to accept the
weights underpinning the aggregation function, for
example, when conducting economic evaluations of
health technologies from a societal perspective.12
But this is not always justified. The use of aggregate
outcome data to inform patient choice raises norma-
tive concerns because it imposes a common valuation
of health dimensions. In fact, reporting relative
hospital performance with respect to risk-adjusted
postoperative EQ-5D utility is only justified if all
(prospective) patients share the same relative values.
But patients may be heterogeneous with respect to
their relative valuations of health dimensions or their
relative valuations may differ from those of the gen-
eral public.13,14 If so, analyzing variation on the level
of health dimensions is more appropriate as it allows
patients to apply their own values when interpreting
performance data.
Third, the use of performance data derived from
EQ-5D utility scores may be limited by patients’ diffi-
culties in interpreting these quantities. In a recent
qualitative study, Hildon and colleagues15 inter-
viewed patients and clinicians about their views on
4 different metrics of hospital PRO performance,
including mean follow-up score, mean change in
score, proportion reaching a specified threshold at
follow-up, and proportion reaching a minimally
important difference. Their results suggest that ‘‘for
patients . . . , unlike measures of height or weight,
PRO . . . scores are unfamiliar and their values have
no immediate meaning. It’s therefore necessary to
transform them into interpretable forms, or indeed
into experiences rather than metrics, to make them
useful.’’15(p11) Furthermore, patients ‘‘could not
distinguish between the four [metrics], but liked
a percentage, or what was for them intuitive sca-
ling.’’15(p10) Analyzing responses on EQ-5D dimen-
sions rather than utility scores allows reporting
performance in a similar form to the way that the
data were originally collected. Hospitals could
then be compared with respect to the risk-adjusted
probability of a given patient to report, for example,
no problems with mobility or pain/discomfort at fol-
low-up.
To explore these claims, we assess hospital perfor-
mance with respect to self-reported health outcomes
for hip replacement patients. We focus on the EQ-5D
and develop a multilevel risk-adjustment model for
each of the 5 functional dimensions. Our approach
draws on the literature on longitudinal modeling16,17
and on cost-effectiveness in multicenter trials18 to
analyze variation in treatment impact across hospi-
tals. More specifically, we model the hospital-spe-
cific contribution to posttreatment EQ-5D response
as a random coefficient that varies between hospitals.
The empirical Bayes (EB) estimates of this coefficient
are then interpreted as capturing relative hospital
quality. We assess the correlation between perfor-
mance assessments on the level of EQ-5D dimensions
and aggregated utility scores.
HOSPITAL VARIATION IN EQ-5D HEALTH OUTCOMES
ORIGINAL ARTICLES 805
 at University of York on August 24, 2016mdm.sagepub.comDownloaded from 
METHODS
Data
Our study exploits EQ-5D data routinely collected
from English patients who had a hip replacement
during April 2009 to March 2010. All providers of
NHS-funded care are required to participate in the
survey.7 This includes all NHS-operated hospitals
and private treatment centers. Patients 15 years or
older who undergo elective, unilateral hip replace-
ment surgery are invited to take part in the survey.19
We extract information on each patient’s pre- and
postoperative EQ-5D health profile and EQ-5D utility
score, in which the latter is calculated using the UK
time tradeoff (TTO) utility weights.20 The pretreat-
ment (baseline) survey is collected either during the
initial outpatient appointment that precedes hospital
admission or at the day of admission. Follow-up data
are collected by the NHS Information Centre via post-
al survey approximately 6 month after surgery. To
ensure consistency with respect to the timing of
measurements while retaining as much information
as possible, we exclude all observations for which
the recorded time between baseline survey and
admission exceeds 12 weeks or the follow-up period
is either shorter than 20 weeks or longer than 1 year.
We link these data to the Hospital Episode Statis-
tics (HES) inpatient database, which contains
detailed information on all inpatient care provided
in English hospitals. The depth of information con-
tained in HES allows us to account for a wide range
of clinical and demographic risk factors. These
include the most frequent main diagnoses (e.g., oste-
oarthritis, rheumatoid arthritis),21 the weighted
Charlson score of comorbidities,22–24 the number of
additionally coded comorbidities, whether it was
a primary or revision surgery and whether the revi-
sion was due to problems with the existing implant,
patient age, sex, and the deprivation profile of the
patient’s neighborhood of residence.25–27 We only
retain patient records that can be matched to the
PRO survey and for which we observe a full EQ-5D
profile at baseline and follow-up.
Statistical Modeling
The objective of the empirical analysis is to obtain
estimates of the relative systematic impact of hospital
providers on patients’ posttreatment health out-
comes. We estimate hierarchical ordered probit
models28–30 separately for each of the 5 EQ-5D
dimensions. We then compare the results with those
obtained from a linear regression on the EQ-5D utility
scores to study thepractical implications of using dis-
aggregated health dimensions for assessment of hos-
pital performance.
Let yijt denote the health status (with respect to, for
example, anxiety/depression) of patient i5 1; . . . ;nj
in hospital j51; . . . ;J at time point t 2 ½0;1. Health
status is assumed to be continuous but not directly
observable. Instead, we observe patients’ own assess-
ment of their status on the 3-point EQ-5D response
scale (m5 1; 2;3with 1 = no problems, 2 = some prob-
lems, 3 = extreme problems). The mapping of latent,
continuous status yijt to observed, discrete responses
yijt is given by the standard threshold model
31
yijt5
3; if yijt  k1
2; if k1\yijt  k2
1; if yijt.k2
8<
: ; ð1Þ
where the threshold parameters k are unobserved and
must be estimated from the data. The categories are
ordered from worst to best. This facilitates the quali-
tative interpretation of regression coefficients, where
a positive sign indicates improvements in latent
health and, thus, the probability of reporting no
problems.
Each patient providesmeasures of his or her health
status pre- and posttreatment. Both responses are out-
comes of the same measurement process as well as
being (partly) determined by common factors, such
as patient characteristics and baseline level of latent
health. Our interest lies in the latent health gain
that follows from hospital treatment and the degree
to which variation in health gain can be systemati-
cally associated with the provider of care. We make
the assumption that, conditional on baseline health
and a set of risk factors, patients do not select into
hospitals based on unobservable characteristics and
that the health of patients in different hospitals
would follow the same trajectory if untreated. This
allows us to interpret the variation in latent health
gain across hospitals as a measure of relative quality
performance.
Our data are characterized by a hierarchical struc-
ture, with measurement points clustered in patients,
which themselves are clustered in hospitals. Given
the nonlinear nature of our model, these data can be
analyzed in 2 ways. One can collapse the hierarchy
into 2 levels and model posttreatment latent health
as a function of lagged, observed (pretreatment)
response yij0, observed patient characteristics, and
a hospital effect.32 Alternatively, one can treat both
GUTACKER AND OTHERS
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pre- and posttreatment latent health as left-hand side
variables and estimate longitudinal models with
unobserved patient heterogeneity.16,17,30 We adopt
the second approach because it allows us a) to explic-
itly account for unobserved, time-invariant determi-
nants of latent health; b) to use information
contained in both observations to estimate threshold
parameters; c) to acknowledge heterogeneity in latent
health within a response group as well as random
noise in reported pretreatment health; and d) to
extend the model in a natural way should more mea-
surement points become available in the future.33
Latent health status at any time point t is then
described by the outcome equation
yijt5aij1 zj1 x
0
ijb1T
ðnj1 x0ijdÞ1 eijt ð2Þ
with
nj5m1 gj: ð3Þ
The vector xij is a set ofpatient-level risk adjustment
variables that are, in this study, time invariant and
assumed to be strictly exogenous. Treatment is mod-
eled as a dummy variable T, which takes a value of 1
if t5 1 (posttreatment) and 0 otherwise. The direct
effect of treatment on posttreatment health is given
by the coefficient nj.Wealso interactTwith xij to allow
for differential effects of patient characteristics on
health status at baseline and on the effect of treatment.
Unexplained variation is decomposed into 4 vari-
ance components: 1) a patient-specific intercept
aij;N 0;s2a
 
that captures unobserved, time-
invariant patient heterogeneity in latent health; 2)
a hospital-specific, time-invariant intercept zj;N
ð0;s2z Þ that addresses hospital clustering; 3) a random
coefficient gj;Nð0;s2gÞ that varies between hospitals
and describes the systematic hospital effect on post-
treatment latent health; and 4) a serially uncorrelated
error term eijt;N 0; 1ð Þ that leads to the well-known
probit specification. Covariance terms between ran-
dom effects on the same level of the hierarchy are
freely estimated, whereas terms across levels are con-
strained to zero. The variance partition coefficient t
describes the extent to which unexplained variation
in posttreatment latent health occurs at the level of
the hospital and is calculated as follows34:
t5
s2g1 2
covðg; zÞ1s2z
s2a1s
2
g1 2
covðg; zÞ1s2z 1s2e
: ð4Þ
Larger values of t indicate that more variation in
posttreatment latent health is attributable to hospital
heterogeneity as captured in the hospital-level inter-
cept and the random coefficient on treatment.
For theEQ-5Dutilitymodel,we adapt (2) to a linear
specification with an identity link function (i.e.,
yijt5 yijt) and eijt;N 0;s2e
 
.
All ordered probit models are estimated by maxi-
mum likelihood using GLLAMM in Stata 11.0 (Stata-
Corp LP, College Station, TX), where the integrals for
the random effects are approximated by adaptive quad-
rature.35 Thresholdparameters and the scale of the coef-
ficient are identified through constraints on the mean
and variance of the error term and themean of the inter-
cept. The linear EQ-5D utility model is estimated by
maximum likelihood using xtmixed in Stata 11.0.
Provider Profiling
Our interest lies in estimates of the relative quality
of each hospital, gj, captured by the hospital-specific
deviation from the average effect of treatment, m. This
parameter is not directly estimated but can be recov-
ered in postestimation using the Bayes theorem with
variance estimates plugged in for the unknown popu-
lation parameters, a technique known as empirical
Bayes prediction.36
For nonlinearmodels, we describe hospital perfor-
mance in 2 different ways. First, we rank hospitals
according to their impact on latent health status yij1.
This can be directly inferred from bgj, wheremore pos-
itive values indicate better performance. Second, we
compute the probability of reporting a specific post-
treatment outcome ðm5 1; 2; 3Þ, based on the esti-
mated quality effort of the hospital. For the average
patient treated in a hospital of average patient intake,
this is given by
Prob yj15mjx; bgj ; caij 5 bzj 5 0
 
5F km  Sj1
 
F km1  Sj1
 
; ð5Þ
where
Sj15 bm1 x0bb1 x0bd1 bgj ð6Þ
and k05 ‘, k35 1‘. We calculate 95% credible
intervals around bgj based on their posterior distribu-
tion.Note that these credible intervals are only appro-
priate for single comparison against a given quantity,
such as the average, but are too wide for direct com-
parisons of specific hospitals.37 Because our interest
is on profiling hospital performance with respect to
treatment impact, we do not consider uncertainty in
other parameters estimates when calculating credible
intervals for Prob yj15m
 
.
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Both methods produce identical rankings of rela-
tive hospital performance. However, only the second
method relates the result back to the original scale of
the PRO survey instrument and allows differences
across hospitals to be investigated in terms of the
probability of achieving a specific health outcome.
RESULTS
Descriptive Statistics and Transition Matrices
Our sample consists of 21,565 patients treated in
153 NHS and private hospitals. The number of
patients in each hospital ranges from 1 to 1106
(mean [SD], 140 [124]). We present descriptive statis-
tics of patient characteristics in Table 1.
Elective hip replacement surgery is performed pre-
dominantly on elderly patients (mean [SD] age, 68.2
[10.5] years), with osteoarthritis being the most com-
mon reason for surgical intervention. The majority of
patients in our sample are female (59.3%) and admit-
ted for primary replacement of the hip joint (92.7%).
The median time elapsed between baseline survey
and date of admission is 14 days (interquartile range
[IQR], 5–28 days). The median follow-up period is
197 days (IQR, 192–209 days).
Table 2 presents the transition matrices for each of
the 5 EQ-5D dimensions. Rows report the patients’
own classification of their status at baseline, and
columns show self-reported status 6months after sur-
gery. Accordingly, patients in the lower triangle
report improvements in health status, whereas those
in the upper triangle report deteriorations.
For each of the 5 dimensions, a considerable num-
ber of patients report no problems at baseline. This is
especially pronounced on the self-care and anxiety/
depression dimensions, in which 44.1% and 57.6%
of patients fall into this category, respectively. Of
the patients, 6.3% report no problems prior to treat-
ment with respect to mobility, whereas nearly all
patients report at least moderate problems with
pain/discomfort (99.1%). Sixty-eight patients report
having no problems in any of the EQ-5D dimensions.
The number of patients improving since treatment
varies greatly by the health dimension under consid-
eration. The dimension most improved since treat-
ment is pain/discomfort, in which 72.3% of the
patients report improvements as indicatedbya transi-
tion to a more favorable category. In contrast, only
29.7% of patients report improvements on the anxi-
ety/depression dimension.
Figure 1 present the empirical distribution of the
EQ-5D utility scores pre- and postintervention. The
mean preintervention score is 0.349, and the mean
postoperative score is 0.761. Both distributions
exhibit typical characteristics of empirical EQ-5D
distribution observed for a wide range of medical
conditions, including multimodality, discontinuity,
and clustering at 1 (‘‘full health’’).38,39 Of the
Table 1 Descriptive Statistics of Patient Characteristics ðN5 21; 565Þ
Variable Description Mean or % SD Min Max
male = 1, if patient is male 40.7%
age Patient’s age in years 68.213 10.465 15 95
wcharlson Weighted Charlson index of comorbidities 0.307 0.647 0 8
add_comorbidities Number of additional comorbidities not included in
Charlson index
1.934 1.859 0 21
deprivation Index of Multiple Deprivation, income domain 0.124 0.095 0.010 0.830
pretest Time between preoperative assessment and admission
(in days)
19.223 18.720 0 84
posttest Follow-up (in days) 205.061 26.912 140 365
Primary surgery
osteoarthritis = 1, if main diagnosis is osteoarthritis (ICD-10: M15-19) 86.5%
rheumatoid_arthritis = 1, if main diagnosis is rheumatoid arthritis (ICD-10:
M05-06)
0.5%
other_maindiag = 1, if main diagnosis is not OA or RA 5.8%
Revision surgery
revision_complications = 1, if revision surgery because of complications with
existing implant (ICD-10: T84)
6.3%
revisions_other = 1, if revision surgery for other reasons 1.0%
ICD-10, International Classification of Diseases, Tenth Revision; OA, osteoarthritis; RA, rheumatoid arthritis.
GUTACKER AND OTHERS
808  MEDICAL DECISION MAKING/AUG 2013
 at University of York on August 24, 2016mdm.sagepub.comDownloaded from 
patients, 87.3% report improvements in health as
measured by the EQ-5D utility index, whereas 6.4%
report deteriorations.
Regression Results
Table 3 presents parameter estimates and associ-
ated standard errors for each of the 5 dimensionmod-
els and the EQ-5D utility index model.
We find several variables to be associated with
self-reported health, both at baseline and follow-up.
These include male sex (1 ), higher weighted Charl-
son index score (–), number of additional comorbid-
ities (–), and the deprivation profile of the patient’s
neighborhood of residence (–). Patients admitted for
primary surgery tend to report worse health status
than those returning for revision surgery related to
complications with their existing implant, but this
effect is only statistically significant for mobility
and pain/discomfort. Similarly, patients with a diag-
nosis of rheumatoid arthritis tend to report lower
levels of health, but the effect is insignificant for the
mobility and anxiety/depression dimensions.
The mean effect of treatment on posttreatment
latent health is positive and significant for all dimen-
sions, resulting in substantial increases in the proba-
bility of reporting no problems after surgery (Table 4).
The number of comorbidities and the indicators for
revision surgery are negatively associated with the
treatment effect, indicating that treatment is less ben-
eficial for multimorbid or revision patients. Simi-
larly, patients living in more deprived areas
experience, on average, less improvement in latent
health than those residing in less deprived areas.
Longer follow-up is also associated with a smaller
increase in postoperative latent health, albeit the
effect being small. For example, for a patient of aver-
age characteristics, the probability of reporting no
problems on anxiety/depression is estimated to
reduce by 0.3% per additional week of follow-up.
Postoperative EQ-5D utility scores are expected to
reduce by 0.0027 per additional week of follow-up.
Table 2 Transition Matrices for All EQ-5D Dimensions
Posttreatment
Pretreatment No (= 1) Some (= 2) Extreme (= 3) Total
Mobility
I have no problems in walking about (= 1) 1122 240 0 1362
I have some problems in walking about (= 2) 10,621 9470 13 20,104
I am confined to bed (= 3) 21 74 4 99
Total 11,764 9784 17 21,565
Self-care
I have no problems with self-care (= 1) 8610 884 13 9507
I have some problems washing or dressing myself (= 2) 7637 4074 65 11,776
I am unable to wash or dress myself (= 3) 78 152 52 282
Total 16,325 5110 130 21,565
Usual activities
I have no problems with performing my usual activities (= 1) 1003 280 24 1307
I have some problems with performing my usual activities (= 2) 8492 7102 420 16,014
I am unable to perform my usual activities (= 3) 1367 2351 526 4244
Total 10,862 9733 970 21,565
Pain/discomfort
I have no pain or discomfort (= 1) 152 45 1 198
I have moderate pain or discomfort (= 2) 7196 4907 237 12,340
I have extreme pain or discomfort (= 3) 3822 4581 624 9027
Total 11,170 9533 862 21,565
Anxiety/depression
I am not anxious or depressed (= 1) 11,449 908 55 12,412
I ammoderately anxious or depressed (= 2) 5477 2405 187 8069
I am extremely anxious or depressed (= 3) 477 450 157 1084
Total 17,403 3763 399 21,565
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All variance components are statistically signifi-
cant at the 95% confidence level as confirmed by like-
lihood ratio tests. In contrast, only the covariance term
in the EQ-5D utility model is statistically significant.
About 1.0% (anxiety/depression) to 4.7% (mobility)
of the unexplained variation in latent health is esti-
mated to be associated with the hospital itself.
Assessment of Hospital Performance
Performance on Individual EQ-5D Dimensions
and EQ-5D Utility Score
Figure 2a–e presents estimates of hospital perfor-
mance on the latent health scale (left graph) and
the probability scale (right graph), where the latter
is calculated for the average patient. Figure 2f
presents the results of the EQ-5D utility model,
where performance is measured directly on the util-
ity scale. Hospitals located to the left side of each
graph perform better than those to the right.
The random coefficient is standardized to zero,
which represents the expected outcome for a hospital
with average case mix. Hospital performance hetero-
geneity, as represented by the slope of the curve, is
most pronounced on themobility and usual activities
dimensions. For the vast majority of hospitals,
credible intervals contain zero, but a small number
of hospitals have a statistically significantly different
treatment impact. Credible intervals on the mobility
dimension are wider than on any other dimension.
This reflects the lesser amount of information con-
tained in the data, with only 2 outcome categories
being reasonably well populated.
Hospital heterogeneity on the latent health scale
translates into differences with respect to hospital-
specific probabilities of reporting a given posttreat-
ment health status. The expected probabilities of
reporting no problems on the usual activities dimen-
sion 6 month after surgery range from 35.8% to
61.8% (calculated for the average patient). In contrast,
expected probabilities for the same outcome on the
self-care dimension are significantly less dispersed
and consistently above 80% for all hospitals. The
probability of reporting extreme problems after sur-
gery is close to zero for all models. We refrain from
reporting credible intervals around these predicted
probabilities to improve the readability of the graphs.
Association of Performance Estimates on EQ-5D
Dimensions and the EQ-5D Utility Index
We explore the global agreement between estimates
of hospital performance based on individual EQ-
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Figure 1 Distribution of EQ-5D utility scores pre- and posttreatment.
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Figure 2 (continued)
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Figure 2 Performance estimates on the latent health and outcome scale: (a) Mobility, (b) Self-Care, (c) Usual Activities, (d) Pain/Discom-
fort, (e) Anxiety/Depression, (f) EQ-5D Utility Index. CI, confidence interval.
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5D dimensions and the utility-weighted EQ-5D
index values by calculating Spearman’s rank corre-
lation coefficients (Spearman’s r) and inspecting
correlation patterns visually (Figure 3).
The highest rank correlation is observed between
performance estimates on the pain/discomfort
dimension and EQ-5D utility index (r = 0.496), fol-
lowed by the anxiety/depression dimension (r =
0.311). The rank correlation for all other dimensions
and the EQ-5D utility index is smaller (r\ 0:2) and,
indeed, not statistically significantly different from
zero for the mobility and usual activities dimensions.
To explore whether judgment about individual
providers would differ depending on which metric
is used to assess performance, we identify providers
with statistically significantly above/below-average
performance on each metric40–42 and compare the
overlap. In 26 of 153 cases, performance classifica-
tions differ across metrics (Table 5).
Eleven hospitals (A–K) are identified as above/
below-average performers according to the EQ-5D util-
ity model but do not stand out on any of the 5 EQ-5D
dimensions. Eight hospitals (L–S) achieve above-aver-
age results with respect to at least 1 dimension of the
EQ-5D, but this performance is not reflected in their
performance estimateonaggregateutilities. Fourhospi-
tals (T–W) fall short of the average benchmark on the
usual activities dimension but would not be identified
as underperformers in terms of their impact onutilities.
Thedisagreement betweenperformance in termsofEQ-
5D utilities and individual dimensions is most appar-
ent in the case of hospital X, where the hospital is clas-
sified as a low performer in terms of its impact on
utilities but is a highperformerwith respect to restoring
its patients’ ability to carry out their usual activities.
DISCUSSION
We set out an analytical strategy to explore patient-
level and hospital-level variation in categorical
responses within and across dimensions of the EQ-
5D. This approach does not require assumptions
about how to aggregate across health dimensions
and offers insight aboutwhich dimensions are partic-
ularly affected by hospital heterogeneity. We find
heterogeneity in performance to bemore pronounced
across the mobility and usual activities dimensions
and less so for the pain/discomfort, anxiety/depres-
sion, and self-care dimensions. Furthermore, we
find that performance on the utility scale correlates
well only with the anxiety/depression and pain/dis-
comfort dimensions. Incidentally, these are the
dimensions that receive the highest weighting in
the UK TTO EQ-5D tariff.20 In contrast, the mobility,
usual activities, and self-care dimensions have rela-
tively lowweights attached to them, andperformance
heterogeneity remains undetected when analyzing
aggregated EQ-5D utility data.
Policy makers are interested in assessing the
change in patient-reported outcomes as a result of
treatment. There are various ways that this change
can be measured and modeled. Our approach has
been tomodel both pre- and posttreatment health sta-
tus as outcomes of the same reporting process and to
conduct multilevel analysis with measurement
points clustered in patients, which themselves are
nested in hospitals. We argue that this is the appro-
priate modeling strategy because it acknowledges
the features of the data-generating process, allows
for patient heterogeneity with respect to observed
and unobserved factors, and makes best use of the
available information. The presented methodology
is readily applicable to other conditions for which
EQ-5D data are collected and, in principle, can be
extended to other PRO instruments.
In recognition of the expectation that health out-
come data are to be used by an audience unfamiliar
with the interpretation of complex statistical results
(e.g., patients and their relatives, family doctors,
managers), we have suggested an intuitively appeal-
ing way of summarizing the differential impact that
Table 4 Predicted Probabilities of Reporting a Given Health Status for a Patient of Average Characteristics
No (= 1) Some (= 2) Extreme (= 3)
t5 1 t5 0 Change t5 1 t5 0 Change t5 1 t5 0 Change
Mobility 0.543 0.026 0.517 0.457 0.974 20.517 0.000 0.001 20.001
Self-care 0.838 0.412 0.426 0.162 0.587 20.425 0.000 0.001 20.001
Usual activities 0.460 0.044 0.416 0.534 0.778 20.244 0.006 0.178 20.172
Pain/discomfort 0.485 0.012 0.473 0.506 0.550 20.044 0.009 0.438 20.429
Anxiety/depression 0.897 0.615 0.282 0.102 0.376 20.274 0.000 0.009 20.009
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hospitals have on treatment outcomes. Our graphical
representation indicates the probability of reporting
a given health outcome and shows how these proba-
bilities vary across health dimensions and hospitals.
Prospective patients (or their agents) who place
greater weight on a particular dimension may use
this information to select a hospital that has a differ-
entially greater impact on this than its peers do.
The primary limitation of our proposed approach
is the increase in dimensionality of the decision prob-
lem for patients. Whereas aggregated scores result in
one estimate of hospital performance, our approach
generates 5 potentially divergent answers. In a recent
study, Dijs-Elsinga and colleagues43 have shown that
a large group of patients favor simple data presenta-
tion and prefer one overall measure of hospital qual-
ity. But many patients intend to use more detailed
quality information when making decisions about
where to seek care in the future.43 The question
then arises about how much information should be
provided for the different objectives for which perfor-
mance information can be used (i.e., patient choice,
accountability, identification of best practice) and
who decides about the relative weighting of each
component and objective.11,44 Our study does not
intend to resolve this debate. Rather, we present
a means of making inferences about hospital quality
and presenting results when health outcomes are
assessed through the EQ-5D PRO instrument. How
best to communicate such performance data requires
careful consideration, to ensure they can be effec-
tively understood and used.
Several issues remain that we have not addressed
in this study. First, based on the full information con-
tained in HES, we can identify those patients who
have not participated or were not included in the
follow-up. We find that, in our data set, only about
50% of eligible hip replacement patients participate
in the baseline survey, with a further 8% dropping
out of the subsequent survey. These numbers should
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improve in time when data collection procedures
becomemore established. However, falsely assuming
that any substantial amount of missing values are
generated at random could lead to biased inferences
from a nonrepresentative population,45 raising ques-
tions about the validity of the assessment.
Second, in this study, we have controlled for
patient risk factors that are deemed clinically rele-
vant, are assumed to be exogenous to the hospital,
and can be derived from routine inpatient records.
However, we do not claim that this set of control var-
iables is exhaustive: Health outcomesmay be affected
by nonrandomly distributed, unobserved patient
characteristics such as severity of the medical condi-
tion or health-related behavior. That said, a strength
of our study is that we control for the initial health
status with which the patient presents at admission.
In many studies, this is unobserved and makes our
analysis more robust than possible in the absence of
such information.
Third, we do not control for characteristics of the
hospital in our analysis, our rationale being that these
arewithin the hospital’s control. But theymay not be.
Hospitals may be constrained in their ability to
choose and combine medical resources to their best
effect by local regulation, access to factor markets,
or, in the short run, the existing capital structure
such as age and functionality and whether the hospi-
tal operates the service over multiple sites.46 In this
case, the assumption of exchangeability underlying
the hierarchical modeling approach may not hold.
Furthermore, procedures such as hip replacement
are generally followed by extensive physical therapy,
which may be delivered outside the hospital. If con-
straints bind or if quality is not attributable solely to
the hospital, our estimates of hospital performance
will be biased.
Fourth, our study makes use of a large administra-
tive data set that contains rich information on patient
characteristics and the type of care provided. The pre-
sented econometric approach is tailored to the data at
hand. However, in other countries or disease areas,
sample sizes may be smaller or information may be
sparse. If patient characteristics are unobserved or
cannot be included due to low degrees of freedom,
then more of the time-invariant variation between
Table 5 Examples of Hospitals for Which Performance Assessments Differ across EQ-5D
Dimensions and the EQ-5D Utility Model
Hospital EQ-5D Utilities Mobility Self-Care Usual Activity Pain/Discomfort Anxiety/Depression
A Below — — — — —
B Below — — — — —
C Below — — — — —
D Below — — — — —
E Below — — — — —
F Below — — — — —
G Above — — — — —
H Above — — — — —
I Above — — — — —
J Above — — — — —
K Above — — — — —
L — Above — — — —
M — Above — — — —
N — — — Above — —
O — — — Above — Above
P — — — Above — —
Q — — — Above — —
R — — — Above — —
S — — — Above — —
T — — — Below — —
U — — — Below — —
V — — — Below — —
W — — — Below — —
X Below — — Above — —
Hospitals are either statistically above or below the average or not different from the average (—).
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patients would be captured by the patient random
effect. Again, the assumption of exchangeability
(i.e., that the unobserved patient heterogeneity is
drawn from a random distribution) may become
unrealistic and results may be biased.47 The same
argument applies to the random coefficient and the
interactions of covariates with the treatment effect.
Researchers will need to consider this limitation
case by case, based on their data and the available
set of risk-adjustment variables.
Finally, further consideration should be given to
the role that patient-reported health outcome perfor-
mance information can play in existing quality
assessment frameworks. Although measures of risk-
adjusted mortality, readmission, and adverse events
have been criticized for their limited granularity
and sensitivity,48 one should not a priori dismiss
their ability to identify high- and low-quality pro-
viders of care. Further research is required to estab-
lish the additional value of outcome data for
hospital quality assessments and contrast it to the
costs of collection.
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